Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.

TitleEnhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.
Publication TypeJournal Article
Year of Publication2014
AuthorsKlein F, Nogueira L, Nishimura Y, Phad G, West AP, Halper-Stromberg A, Horwitz JA, Gazumyan A, Liu C, Eisenreich TR, Lehmann C, Fätkenheuer G, Williams C, Shingai M, Martin MA, Bjorkman PJ, Seaman MS, Zolla-Pazner S, Karlsson Hedestam GB, Nussenzweig MC
JournalJ Exp Med
Volume211
Issue12
Pagination2361-72
Date Published11/17/2014
ISSN1540-9538
Abstract

Antibody-mediated immunotherapy is effective in humanized mice when combinations of broadly neutralizing antibodies (bNAbs) are used that target nonoverlapping sites on the human immunodeficiency virus type 1 (HIV-1) envelope. In contrast, single bNAbs can control simian-human immunodeficiency virus (SHIV) infection in immune-competent macaques, suggesting that the host immune response might also contribute to the control of viremia. Here, we investigate how the autologous antibody response in intact hosts can contribute to the success of immunotherapy. We find that frequently arising antibodies that normally fail to control HIV-1 infection can synergize with passively administered bNAbs by preventing the emergence of bNAb viral escape variants.

DOI10.1084/jem.20141050
Alternate JournalJ. Exp. Med.
PubMed ID25385756
PubMed Central IDPMC4235636
Grant List#UL1 TR000043 / TR / NCATS NIH HHS / United States
AI 100148-01 / AI / NIAID NIH HHS / United States
AI 100663-01 / AI / NIAID NIH HHS / United States
P01 AI100148 / AI / NIAID NIH HHS / United States
P01AI100151 / AI / NIAID NIH HHS / United States
R01 HL59725 / HL / NHLBI NIH HHS / United States
T32 AI070084 / AI / NIAID NIH HHS / United States
UM1AI100663 / AI / NIAID NIH HHS / United States
/ / Howard Hughes Medical Institute / United States
CHAVI-ID: 
1
Cover Picture: